Emami Ltd (NSE: EMAMILTD) – Comprehensive Equity Research Report

Published: June 2026 | Sector: FMCG – Personal Care & Healthcare

Company Overview

Emami Ltd is one of India's leading Fast-Moving Consumer Goods (FMCG) companies, engaged in the manufacturing and marketing of personal care and healthcare products. The company boasts an enviable portfolio of household brand names including BoroPlus (antiseptic cream), Navratna (cool oil), Zandu Balm (pain relief), Fair and Handsome (men's fairness cream), Kesh King (medicinal hair oil), Zandu Pancharishta, and Mentho Plus Balm. Founded in 1974 and headquartered in Kolkata, Emami has built a strong presence across India's rural and urban markets while expanding its footprint internationally across the Middle East, Africa, and South Asia.

The company operates in the personal products and personal care sub-segments of the FMCG sector, commanding significant market share in niche categories like pain balms, antiseptic creams, and men's grooming. Emami is listed on both the National Stock Exchange (NSE: EMAMILTD) and the Bombay Stock Exchange (BSE: 531162), and is a constituent of the BSE 500, Nifty 500, Nifty FMCG, and BSE Fast Moving Consumer Goods indices.

Key Financial Metrics at a Glance

Financial Performance Analysis

Revenue & Sales Growth

Emami's consolidated revenue trajectory over the past decade tells a story of moderate but steady growth tempered by recent headwinds. Annual consolidated sales have grown from ₹2,076 Cr in FY2015 to ₹3,780 Cr in FY2026, reflecting a 10-year compounded sales growth rate of approximately 5%. However, the 5-year sales growth stands at 6%, while the 3-year growth has decelerated to 4%, and the trailing twelve months (TTM) sales growth is -1%, indicating near-term revenue pressure.

Annual Revenue Trajectory (Consolidated):

The FY2026 revenue decline of -0.8% marks the first annual contraction since FY2020, when the COVID-19 pandemic disrupted consumer spending. The Q4 FY2026 standalone sales of ₹925 Cr represented a -3.94% year-on-year decline, reflecting broader FMCG sector headwinds including rural demand softness, input cost pressures, and competitive intensity.

Profitability Analysis

Despite modest revenue growth, Emami has demonstrated impressive profit expansion driven by operating leverage and cost optimization. The company's consolidated net profit grew from ₹485 Cr in FY2015 to ₹775 Cr in FY2026, reflecting a 10-year compounded profit growth rate of 7% and a 5-year profit growth rate of 13%.

Annual Profitability (Consolidated):

Key observations from the profitability data:

• Operating margins have remained resilient in the 25-31% band over the past decade, averaging approximately 27%, demonstrating the strength of Emami's brand portfolio and pricing power.
• FY2026 operating profit declined by 5.3% to ₹960 Cr from ₹1,014 Cr in FY2025, with OPM contracting to 25% from 27%, reflecting higher input costs and competitive pricing pressure.
• Net profit declined marginally by 3.5% in FY2026 to ₹775 Cr, though the EPS fell to ₹17.76 from ₹18.48 in FY2025.
• The exceptional net profit of ₹837 Cr in FY2022 was driven by a negative tax rate of -22%, likely due to reversals of deferred tax liabilities or one-time tax benefits.

Quarterly Performance Trends

The quarterly data reveals the volatile and seasonal nature of Emami's business, with Q4 (January-March) typically being the strongest quarter due to winter-related product demand (pain balms, cold creams).

Recent Quarterly Performance (Consolidated):

Notable quarterly observations:

• Q3 FY2026 was the standout quarter with ₹1,152 Cr in sales (highest ever) and ₹319 Cr net profit at 33% OPM, benefiting from the festive-winter season.
• Q4 FY2026 showed weakness with ₹925 Cr in sales (down -3.94% YoY) and ₹143 Cr net profit (down -11.71% YoY), with OPM declining to 20% — the lowest in recent quarters.
• The quarterly profit variance of -11.71% in Q4 FY2026 is a concern, reflecting margin compression from higher raw material costs and increased advertising spends.

Balance Sheet Strength

Emami maintains a robust balance sheet with minimal debt and strong asset quality. The company has been virtually debt-free for most of the past five years, a significant advantage in the capital-intensive FMCG sector.

Balance Sheet Highlights (Consolidated, ₹ Crore):

Key balance sheet observations:

• Total reserves have grown from ₹1,208 Cr in FY2015 to ₹2,880 Cr in FY2026, reflecting consistent profit retention.
• Borrowings remain minimal at ₹162 Cr (FY2026), up slightly from ₹90 Cr in FY2025, but still negligible relative to the ₹3,836 Cr total asset base.
• Fixed assets have been declining steadily from ₹1,459 Cr in FY2020 to ₹887 Cr in FY2026, indicating an asset-light business model with reduced capital intensity following divestiture of non-core assets.
• Investments have surged from ₹156 Cr in FY2020 to ₹834 Cr in FY2026, reflecting strategic investments in subsidiaries, associates, and financial instruments.
• Net worth stands at approximately ₹2,924 Cr (Equity + Reserves), translating to a book value per share of ₹67.0.
• The debt-to-equity ratio is negligible at approximately 0.06x, confirming the company's virtually debt-free status.

Cash Flow Analysis

Emami's cash flow generation is one of its strongest financial attributes. The company consistently converts a high proportion of its operating profits into actual cash, as evidenced by the CFO-to-Operating Profit ratio averaging approximately 100% over the past decade.

Cash Flow Summary (Consolidated, ₹ Crore):

Key cash flow observations:

• Cash from operations has grown from ₹534 Cr in FY2015 to ₹801 Cr in FY2026, demonstrating consistent operational cash generation.
• Free cash flow stood at ₹770 Cr in FY2026, a slight decline from ₹852 Cr in FY2025, but still robust.
• Cumulative free cash flow over the past 5 years (FY2022-FY2026) totals approximately ₹3,295 Cr, an impressive figure for a company with a market cap of ₹17,355 Cr (implying an FCF yield of approximately 4.5% on a trailing 5-year average basis).
• The company has been consistently returning cash to shareholders through dividends, as evidenced by the persistent negative financing cash flows (averaging -₹500 Cr to -₹550 Cr annually).
• The CFO/Operating Profit ratio has averaged approximately 100% over the past decade, indicating high-quality earnings with minimal accrual-related distortions.

Key Financial Ratios

Efficiency Ratios

Key ratio observations:

• Debtor days have improved significantly from 50 days in FY2024 to 33 days in FY2026, reflecting better collection efficiency and healthier trade receivables.
• Inventory days have increased sharply from 94 days in FY2025 to 128 days in FY2026, a potential red flag suggesting slower inventory turnover or inventory build-up ahead of anticipated demand.
• Days payable have stretched to 153 days in FY2026, the highest in the decade, indicating Emami's strong bargaining power with suppliers.
• The cash conversion cycle remains efficient at 8 days, though it deteriorated from 4 days in FY2025.
• Working capital days have increased from 25 in FY2025 to 66 in FY2026, driven primarily by the inventory build-up.
• ROCE has stabilized around 29-32% over the past four years, demonstrating consistent capital efficiency. The 10-year average ROCE of approximately 28% is impressive for an FMCG company.

Return Ratios

The consistent ROE of 26-31% over various time frames underscores Emami's ability to generate superior returns on shareholders' equity. The 3-year average ROE of 29.3% is particularly commendable and places Emami among the top performers in the Indian FMCG sector.

Dividend History & Shareholder Returns

Emami has maintained a healthy and consistent dividend payout policy, with an average payout ratio of 45.4% over recent years.

Dividend Payout History:

At the current market price of ₹398 and a dividend yield of 2.52%, Emami offers an attractive income stream relative to many FMCG peers. The FY2026 payout ratio of 34% is lower than historical averages, possibly reflecting management's decision to retain more earnings for strategic investments, including the recent IncNut Digital acquisition. The total dividends paid over the past 5 years (FY2022-FY2026) would amount to approximately ₹1,600 Cr, demonstrating strong commitment to shareholder returns.

Stock Price Performance

Emami's stock has significantly underperformed the broader market and FMCG indices over multiple time frames, reflecting the market's concerns about slowing growth and competitive pressures.

Stock Price CAGR:

The stock is currently trading at ₹398, down -37.5% from its 52-week high of ₹635 and near its 52-week low of ₹385. This significant correction has compressed the P/E multiple to 22.1x, which is substantially below the sector median P/E of approximately 39.9x among personal care FMCG peers.

Valuation Context:

The P/E discount to the sector suggests the market is pricing in slower growth expectations for Emami relative to larger FMCG peers like Godrej Consumer (P/E: 50.9x), Dabur India (P/E: 39.5x), and Colgate-Palmolive (P/E: 40.3x). However, this valuation gap also presents a potential re-rating opportunity if the company can reignite its growth engine.

Peer Comparison

Emami operates in a competitive landscape alongside some of India's largest FMCG companies. Here's how it stacks up against key peers:

Key competitive observations:

• Emami is the most attractively valued among its FMCG peers at 22.1x P/E, roughly 45% cheaper than the peer median of ~40x P/E.
• Emami's dividend yield of 2.52% is the highest among major FMCG peers, offering superior income.
• However, Emami is the only major FMCG company among this group to report negative quarterly profit growth (-11.71%) and negative sales growth (-3.94%).
• Colgate-Palmolive and P&G Hygiene have exceptionally high ROCEs (108% and 157% respectively), but these are largely due to their asset-light distribution models in India and may not be directly comparable.
• Emami's ROCE of 29.56% is competitive and demonstrates efficient capital allocation.

Shareholding Pattern Analysis

The shareholding pattern reveals significant shifts in institutional ownership over the past few years.

Current Shareholding (Q4 FY2026 – March 2026):

Shareholding Trend Analysis:

Key shareholding observations:

• Promoter holding has been stable at 54.84% since FY2024, down from a peak of 72.74% in FY2017. The 20 percentage point reduction over the past decade was primarily done through block deals and strategic placements to improve liquidity and institutional participation.
• FII holding has declined sharply from 14.38% in September 2024 to 8.57% in March 2026, a drop of nearly 6 percentage points in 18 months. This sustained foreign selling is a significant headwind and likely reflects global portfolio rebalancing and concerns about Emami's growth trajectory.
• DII holding has increased from 21.51% in September 2024 to 26.91% in March 2026, indicating domestic institutional confidence in the company's long-term prospects. This increase partially offsets FII selling.
• Retail/public holding stands at 9.67% with 1,27,615 shareholders, up from 97,043 shareholders in FY2023, indicating broader retail participation.
• A recent SEBI disclosure (25-27 May 2026) revealed that Diwakar Finvest and Suraj Finvest created pledges on 23.5 lakh Emami shares, which warrants monitoring as promoter-affiliated entities pledging shares can signal financial stress (though this appears to be a relatively small transaction).

Strategic Developments & Recent News

IncNut Digital Acquisition (June 2026)

In a significant strategic move, Emami completed the acquisition of 59.69% stake in IncNut Digital on 1 June 2026, making it a subsidiary. IncNut Digital is a digital-first beauty and wellness company that operates popular brands in the online space. This acquisition aligns with Emami's strategy to:

• Strengthen its digital and e-commerce capabilities
• Access a younger, digitally-native consumer base
• Diversify its distribution channels beyond traditional retail
• Build a portfolio of modern, D2C (direct-to-consumer) brands

The acquisition comes at a time when e-commerce contribution to FMCG sales is rising rapidly in India, and Emami has been investing to grow its online presence. The company's e-commerce contribution to domestic sales has been growing year-on-year, though specific figures are behind Screener.in's login wall.

Other Recent Developments

• Annual Secretarial Compliance Report filed for FY2026 with no non-compliances reported by auditors, reflecting strong governance standards.
• Audited financial results for FY2026 were published on 22 May 2026 in leading newspapers.
• Earnings call transcript was made available on 25 May 2026, providing management commentary on quarterly performance and outlook.

Investment Thesis: Strengths

1. Iconic Brand Portfolio with Market Leadership

Emami owns some of India's most iconic and recognizable personal care brands. BoroPlus is the market leader in the antiseptic cream category, Navratna dominates the cool oil segment, Zandu Balm is the leading pain balm brand, and Kesh King holds a significant share in the medicinal hair oil segment. These brands enjoy strong consumer loyalty, high recall, and pricing power, which provides a durable competitive moat.

2. Asset-Light, Cash-Generative Business Model

The company's negligible debt (borrowings of just ₹162 Cr against total assets of ₹3,836 Cr), consistent free cash flow generation (₹770 Cr in FY2026), and high CFO/Operating Profit conversion (~100%) make it one of the most financially resilient companies in the FMCG sector. The debt-to-equity ratio of approximately 0.06x provides significant financial flexibility.

3. Superior Return Ratios

The 3-year average ROE of 29.3% and ROCE of 29.6% place Emami among the top-performing FMCG companies in India in terms of capital efficiency. These returns are achieved without excessive leverage, demonstrating the inherent strength of the business model.

4. Attractive Valuation

At 22.1x P/E, Emami trades at a 45% discount to the FMCG sector median of 39.9x. The Price-to-Book ratio of ~5.9x and EV/EBITDA of approximately 15x (estimated) are also reasonable for a company with 25%+ operating margins and near-zero debt. The dividend yield of 2.52% provides downside support.

5. Strong Domestic Distribution Network

Emami has built an extensive distribution network spanning millions of retail outlets across India, with particular strength in semi-urban and rural markets where its pain relief and antiseptic brands have deep penetration. The company has also been investing in direct retail reach and modern trade channels.

Investment Thesis: Risks & Concerns

1. Slowing Revenue Growth

The 5-year sales CAGR of just 6% and TTM sales growth of -1% are concerning for an FMCG company. The Q4 FY2026 sales decline of -3.94% YoY suggests that the near-term growth trajectory remains challenged. The poor sales growth of 5.58% over the past five years is a legitimate concern that the market has rightly penalized.

2. FII Exodus

The sustained decline in FII holding from 14.38% to 8.57% over 18 months is a significant overhang. Foreign institutional investors have been net sellers of Emami shares, likely due to relative underperformance, growth concerns, and global portfolio rebalancing away from mid-cap FMCG stocks.

3. Competitive Intensity

The personal care and healthcare segments in India are witnessing increasing competition from both large multinational corporations (Unilever, P&G) and emerging D2C brands that are leveraging digital channels to reach consumers directly. This competitive pressure could impact Emami's market share, pricing power, and margins.

4. Working Capital Deterioration

Working capital days have increased from 25 in FY2025 to 66 in FY2026, and inventory days have jumped from 94 to 128. While the improvement in debtor days from 43 to 33 is positive, the overall working capital cycle deterioration warrants monitoring as it could signal demand softness or distribution challenges.

5. Low Tax Rate Concern

The company has historically operated at tax rates significantly below the statutory rate (averaging 8-10% versus the statutory 25-30%). While this has boosted reported profits, the low tax rate may not be sustainable indefinitely and could normalize, impacting future earnings. The FY2026 blended tax rate was approximately 8%.

6. Concentration Risk

Emami's revenue is heavily concentrated in a few key brands and categories (pain relief, antiseptic, hair oil). Any adverse development affecting these flagship brands could disproportionately impact the company's financial performance.

Management & Corporate Governance

Emami is a family-promoted company with the Agarwal family maintaining a 54.84% promoter stake. The company has been progressively professionalizing its management while maintaining family oversight on strategic decisions. Key governance observations:

• Promoter holding has been stable, with no recent selling activity.
• The company has maintained consistent dividend payments even during difficult years, demonstrating commitment to minority shareholders.
• Secretarial compliance reports show no non-compliances, indicating robust governance practices.
• The pledge on 23.5 lakh shares by promoter-affiliated entities (Diwakar Finvest, Suraj Finvest) in May 2026 is relatively minor but needs to be tracked.

Valuation Analysis

Current Valuation Metrics

Valuation Perspective

At 22.1x trailing P/E, Emami is trading at a significant discount to its historical average P/E of approximately 30-35x and to the FMCG sector median of 39.9x. This discount reflects the market's pricing of slower growth, competitive headwinds, and FII selling pressure.

However, for a company with:

• ~₹770 Cr annual free cash flow
• 29.6% ROCE
• Near-zero debt
• 2.52% dividend yield
• Iconic brand portfolio

The current valuation appears to adequately discount the near-term risks while offering reasonable upside potential if the company can deliver on growth acceleration through new product launches, digital initiatives, and the IncNut Digital acquisition.

Fair value range estimate: Based on a 25-30x P/E on normalized EPS of ₹18-20, the fair value range would be approximately ₹450-600, suggesting 13-50% upside from the current price of ₹398.

Pros & Cons Summary

✅ Pros

• Company is almost debt-free with borrowings of just ₹162 Cr against ₹3,836 Cr total assets
• Strong ROE track record: 3-Year average ROE of 29.3%, consistently above 26% over the decade
• Healthy dividend payout of 45.4% average, with a current yield of 2.52%
• Debtor days improved from 42.3 to 33.2 days, reflecting better collection efficiency
• Robust free cash flow generation of ₹770 Cr in FY2026
• Iconic brand portfolio with market leadership in pain relief, antiseptic, and hair care
• Attractive valuation at 45% discount to FMCG sector P/E

⚠️ Cons

• Poor sales growth of 5.58% over the past five years
• Tax rate seems low at ~8% versus statutory 25%, posing normalization risk
• Working capital days increased from 40.4 to 66.3 days, driven by inventory build-up
• FII holding declined sharply from 14.38% to 8.57% in 18 months
• Q4 FY2026 showed weakness with -3.94% sales growth and -11.71% profit decline
• Stock price declined 32% over the past year, reflecting market concerns

Conclusion

Emami Ltd represents a classic quality FMCG company going through a cyclical trough. The company's iconic brands, asset-light model, superior return ratios, and near-zero debt provide a strong foundation. However, slowing revenue growth, competitive intensity, FII exodus, and working capital concerns have weighed on the stock.

At the current price of ₹398 and a P/E of 22.1x, the stock appears to be fairly valued to slightly undervalued for long-term investors who believe in the company's brand strength and management's ability to reignite growth. The dividend yield of 2.52% provides a cushion while waiting for a growth recovery.

Key catalysts to watch:

• Integration and performance of the IncNut Digital acquisition
• Rural demand recovery and overall FMCG sector sentiment
• Stabilization of FII holdings and potential DII accumulation
• Working capital normalization (particularly inventory days)
• New product launches and market share trends in key categories

For value-oriented investors with a 3-5 year horizon, Emami offers an compelling risk-reward proposition at current levels, with the stock trading at a multi-year low valuation relative to its earnings power and balance sheet strength.